ARCHIVES

FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate.

This article is from The Cancer Letter archive.

Vol. 30 No. 22 | May 28, 2004

Download PDF Visit The Full Archive

Related Articles

New Concept For Prevention Units Goes to DCPC BSC

April 24, 1987

Cancer Letter Adds Associate Editor

July 19, 1985

Ronald DePinho Apologizes, Takes Responsibility For “Morale Issues” at MD Anderson

September 27, 2013

NCI, FDA Are Feuding Again, This Time Overcharge That DCT Moved Too Slowly On Toxicity Notification

April 10, 1981

Skipper, Cohen, Burkitt Win GM $100,000 awards, Medal

June 18, 1982

Oklahoma Cancer Center Recruits Four Professors.

June 15, 2001